A New Dawn in Cardiovascular Protection III

Friday 28th - Saturday 29th April 2006

A New Dawn in Cardiovascular Protection III

Lisbon, Portugal

Cardiovascular disease causes nearly one-third of deaths worldwide. In addition, a cardiovascular event causes worse quality of life. The current educational activity features presentations that examine how we can improve patient prognosis.

Sustained and powerful control of blood pressure is important in reducing heart disease and preventing stroke. Obesity, insulin resistance and dyslipidaemia, as well as hypertension, are important contributory risk factors to cardiovascular disease and are components of the metabolic syndrome. The importance of the metabolic syndrome in diagnosis and treatment is discussed. Lifestyle modifications can make major contributions to reducing body weight and improving waist-to-hip ratios. Angiotensin receptor blockers (ARBs) are effective antihypertensive agents, and some ARBs may have additional beneficial effects in patients with hypertension and insulin resistance.

Both diabetes and hypertension increase the risk of cardiovascular disease and chronic renal disease. Blocking the renin-angiotensin system (for example with ARBs) lowers blood pressure and also reduces the damaging effect of angiotensin II on target organs. This may reduce progression of cardiovascular and renal disease. There is the prospect that dual blockade of the RAAS may provide enhanced target-organ protection and prevent debilitating and life-threatening cardiovascular damage. This hypothesis is being tested in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial.

Faculty

Meeting Chairmen

• Giuseppe Mancia - Department of Clinical Medicine San Gerardo Hospital, Monza-Milan, Italy
• Eberhard Ritz - Department of Nephrology Ruprecht-Karls University Heidelberg, Heidelberg, Germany

Session Chairmen

• Toshiro Fujita - Department of Nephrology and Endocrinology The University of Tokyo, Tokyo, Japan
• Victor Dzau - Office of the Chancellor Duke University Medical Center, North Carolina, USA
• Björn Dahlöf - Department of Medicine Sahlgrenska University Hospital, Gothenburg, Sweden
• Peter Sleight - Cardiovascular Medicine John Radcliffe Hospital, Oxford, UK

Speakers

• Giuseppe Mancia - Department of Clinical Medicine San Gerardo Hospital, Monza-Milan, Italy
• William B White - Department of Hypertension/Medicine University of Connecticut School of Medicine, Connecticut, USA
• Björn Dahlöf - Department of Medicine Sahlgrenska University Hospital, Gothenburg, Sweden
• Theodore W Kurtz - Department of Laboratory Medicine University of California at San Francisco, San Francisco, USA
• Arya M Sharma - Department of Medicine McMaster University, Hamilton, Canada
• Victor Dzau - Office of the Chancellor Duke University Medical Center, North Carolina, USA
• Dick de Zeeuw - Department of Clinical Pharmacology University Medical Center, Groningen, The Netherlands
• Toshiro Fujita - Department of Nephrology and Endocrinology The University of Tokyo, Tokyo, Japan
• Jan Galle Klinikum - Lüdenscheid Lüdenscheid, Germany
• Thomas Unger - Institute of Pharmacology and Toxicology Charite - University Medicine, Berlin, Germany
• Stevo Julius - Department of Internal Medicine University of Michigan Health System, Michigan, USA
• Michael Böhm - Department of Internal Medicine Cardiology and Angiology University of the Saarland Homburg/Saar, Germany
• Michael A Weber - Medical College of the State University of New York New York, USA
• Eberhard Ritz - Department of Nephrology Ruprecht-Karls University - Heidelberg, Heidelberg, Germany

Agenda - Friday 28th April 2006

Hypertension and the diabetogenic risk

• Welcome and opening remarks - Joao Saavedra, Portugal / Eberhard Ritz, Germany
• Blood pressure reduction and cardiovascular outcomes: accumulated evidence over the last 50 years - Giuseppe Mancia, Italy
• Aggressive blood pressure lowering when it matters most - William B White, USA
• Prevention of stroke in hypertensive patients - Björn Dahlöf, Sweden
• Beyond the classical ARB profile - Theodore W Kurtz, USA
• Obesity and the value of lifestyle modifications - Arya M Sharma, Canada
• Does the term metabolic syndrome add to diagnosis and treatment? - No it does not / Dick de Zeeuw, The Netherlands - Yes it does / Victor Dzau, USA
• Questions from the audience
• Panel discussion

Agenda - Saturday 29th April 2006

High-risk patients and multi-factorial treatment

• Reduction of proteinuria with ARBs - Jan Galle, Germany
• Renal dysfunction: extremely common and a silent killer - Dick de Zeeuw, The Netherlands
• Rationale for double renin-angiotensin-aldosterone blockade - Thomas Unger, Germany
• Blood pressure versus beyond: has the jury reached its verdict? - Stevo Julius, USA
• ARBs versus ACE inhibitors: where do we stand now? - Michael Böhm, Germany
• A landmark in cardiovascular patient management: the combination of ACE inhibitors and ARBs from a clinical perspective - Michael Weber, USA
• Multi-factorial treatment: the solution for total cardiovascular risk management - Eberhard Ritz, Germany
• Panel discussion
• Closing Remarks - Giuseppe Mancia, Italy

To start the webcast "A New Dawn in Cardiovascular Protection III" choose one of the following sessions:

• 28 April 2006 - Session 1
• 28 April 2006 - Session 2
• 29 April 2006 - Session 1
• 29 April 2006 - Session 2

Each session contains a large volume of data. You can play the programme straight away, however the 'forward/reverse' and 'advance to slide' functions will not operate until all the data has downloaded. Depending on the capacity of your internet connection, this may take several minutes. To enable direct positioning to a topic of the video webcast behind a firewall Microsoft Mediaplayer should use MMS (TCP) instead of HTTP protocol. To do this please open port 1755 TCP for this IP-destination (193.99.41.51) or in general.